SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-18-000075
Filing Date
2018-01-29
Accepted
2018-01-29 17:29:28
Documents
2
Group Members
ORBIMED CAPITAL GP V LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 9 ss77139_sc13da.htm SC 13D/A 120187
2 JOINT FILING AGREEMENT ss77139_ex9901.htm EX-99.1 23876
  Complete submission text file 0000947871-18-000075.txt   145589
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address TUBORG BOULEVARD 5 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 5 HELLERUP G7 DK-2900 45 36 94 44 86
Ascendis Pharma A/S (Subject) CIK: 0001612042 (see all company filings)

IRS No.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88586 | Film No.: 18556891
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1